BACKGROUND/AIMS: Although HIV-infected persons are at higher risk for acute kidney injury (AKI) during hospitalization compared with their uninfected counterparts, risk factors for AKI are not well-defined. We aimed to describe the evolving incidence of AKI among HIV-infected individuals and to identify important AKI risk factors. METHODS: We conducted a prospective cohort study of 56,823 HIV-infected persons in the Department of Veterans Affairs Clinical Case Registry. Outcomes were: AKI (acute in-hospital serum creatinine increase of ≥0.3 mg/dl, or a relative increase by 50% or greater), and dialysis-requiring AKI. We used proportional hazards regressions to identify risk factors. RESULTS: From its peak in 1995 at 62 per 1,000 person-years, the incidence of AKI declined after the introduction of highly active antiretroviral therapy (HAART) in 1996 to a low point of 25 per 1,000 person-years in 2006. Incidence of dialysis-requiring AKI declined in the early 1990s, but doubled between 2000 and 2006. Using multivariate proportional hazard regression, we identified the following strong risk factors for AKI: chronic kidney disease (eGFR <60 ml/min/1.73 m(2)) (5.38, 95% CI: 5.11-5.67), proteinuria (1.78, 1.70-1.87), low serum albumin (<3.7 mg/dl) (5.24, 4.82-5.71), low body mass index (<18.5 kg/m(2)) (1.69, 1.54-1.86), cardiovascular disease (1.77, 1.66-1.89), low CD4 count (<200 cells/mm(3)) (2.54, 2.33-2.77), and high viral load (≥100,000 copies/ml) (2.51, 2.28-2.75). In addition, there was substantial heterogeneity in the strengths of risk factors for dialysis-requiring AKI before and after the introduction of HAART. CONCLUSIONS: Although AKI incidence has decreased during the HAART era, it remains common in HIV-infected persons and appears attributable to both kidney- and HIV-related factors.
BACKGROUND/AIMS: Although HIV-infectedpersons are at higher risk for acute kidney injury (AKI) during hospitalization compared with their uninfected counterparts, risk factors for AKI are not well-defined. We aimed to describe the evolving incidence of AKI among HIV-infected individuals and to identify important AKI risk factors. METHODS: We conducted a prospective cohort study of 56,823 HIV-infectedpersons in the Department of Veterans Affairs Clinical Case Registry. Outcomes were: AKI (acute in-hospital serum creatinine increase of ≥0.3 mg/dl, or a relative increase by 50% or greater), and dialysis-requiring AKI. We used proportional hazards regressions to identify risk factors. RESULTS: From its peak in 1995 at 62 per 1,000 person-years, the incidence of AKI declined after the introduction of highly active antiretroviral therapy (HAART) in 1996 to a low point of 25 per 1,000 person-years in 2006. Incidence of dialysis-requiring AKI declined in the early 1990s, but doubled between 2000 and 2006. Using multivariate proportional hazard regression, we identified the following strong risk factors for AKI: chronic kidney disease (eGFR <60 ml/min/1.73 m(2)) (5.38, 95% CI: 5.11-5.67), proteinuria (1.78, 1.70-1.87), low serum albumin (<3.7 mg/dl) (5.24, 4.82-5.71), low body mass index (<18.5 kg/m(2)) (1.69, 1.54-1.86), cardiovascular disease (1.77, 1.66-1.89), low CD4 count (<200 cells/mm(3)) (2.54, 2.33-2.77), and high viral load (≥100,000 copies/ml) (2.51, 2.28-2.75). In addition, there was substantial heterogeneity in the strengths of risk factors for dialysis-requiring AKI before and after the introduction of HAART. CONCLUSIONS: Although AKI incidence has decreased during the HAART era, it remains common in HIV-infectedpersons and appears attributable to both kidney- and HIV-related factors.
Authors: Nora Franceschini; Sonia Napravnik; William F Finn; Lynda A Szczech; Joseph J Eron Journal: J Acquir Immune Defic Syndr Date: 2006-07 Impact factor: 3.731
Authors: Morgan E Grams; Brad C Astor; Lori D Bash; Kunihiro Matsushita; Yaping Wang; Josef Coresh Journal: J Am Soc Nephrol Date: 2010-07-29 Impact factor: 10.121
Authors: Christopher Keller; Ronit Katz; Mark J Sarnak; Linda F Fried; Bryan Kestenbaum; Mary Cushman; Michael G Shlipak Journal: Nephrol Dial Transplant Date: 2009-09-03 Impact factor: 5.992
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Girish N Nadkarni; Achint A Patel; Rabi Yacoub; Alexandre M Benjo; Ioannis Konstantinidis; Narender Annapureddy; Shiv Kumar Agarwal; Priya K Simoes; Sunil Kamat; Madhav C Menon; Christina M Wyatt Journal: AIDS Date: 2015-06-01 Impact factor: 4.177
Authors: Anthony N Muiru; Erin Madden; Ani Chilingirian; Anna D Rubinsky; Rebecca Scherzer; Richard Moore; Celia P Corona Villalobos; Jose Manuel Monroy Trujillo; Chirag R Parikh; Chi-Yuan Hsu; Michael G Shlipak; Michelle M Estrella Journal: HIV Med Date: 2021-12-12 Impact factor: 3.094
Authors: Charlotte Schutz; David R Boulware; Katherine Huppler-Hullsiek; Maximilian von Hohenberg; Joshua Rhein; Kabanda Taseera; Friedrich Thienemann; Conrad Muzoora; David B Meya; Graeme Meintjes Journal: Open Forum Infect Dis Date: 2017-06-20 Impact factor: 3.835
Authors: Udeme E Ekrikpo; Andre P Kengne; Aminu K Bello; Emmanuel E Effa; Jean Jacques Noubiap; Babatunde L Salako; Brian L Rayner; Giuseppe Remuzzi; Ikechi G Okpechi Journal: PLoS One Date: 2018-04-16 Impact factor: 3.240